Literature DB >> 25101889

Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus.

Xiang-ni Wu1, Yan-xia Ye1, Jing-wen Niu1, Yang Li1, Xin Li1, Xin You1, Hua Chen1, Li-dan Zhao1, Xiao-feng Zeng1, Feng-chun Zhang1, Fu-lin Tang1, Wei He2, Xue-tao Cao2, Xuan Zhang3, Peter E Lipsky4.   

Abstract

PTEN regulates normal signaling through the B cell receptor (BCR). In systemic lupus erythematosus (SLE), enhanced BCR signaling contributes to increased B cell activity, but the role of PTEN in human SLE has remained unclear. We performed fluorescence-activated cell sorting analysis in B cells from SLE patients and found that all SLE B cell subsets, except for memory B cells, showed decreased expression of PTEN compared with B cells from healthy controls. Moreover, the level of PTEN expression was inversely correlated with disease activity. We then explored the mechanisms governing PTEN regulation in SLE B cells. Notably, in normal but not SLE B cells, interleukin-21 (IL-21) induced PTEN expression and suppressed Akt phosphorylation induced by anti-immunoglobulin M and CD40L stimulation. However, this deficit was not primarily at the signaling or the transcriptional level, because IL-21-induced STAT3 (signal transducer and activator of transcription 3) phosphorylation was intact and IL-21 up-regulated PTEN mRNA in SLE B cells. Therefore, we examined the expression of candidate microRNAs (miRs) that could regulate PTEN: SLE B cells were found to express increased levels of miR-7, miR-21, and miR-22. These miRs down-regulated the expression of PTEN, and IL-21 stimulation increased the expression of miR-7 and miR-22 in both normal and SLE B cells. Indeed, a miR-7 antagomir corrected PTEN-related abnormalities in SLE B cells in a manner dependent on PTEN. Therefore, defective miR-7 regulation of PTEN contributes to B cell hyperresponsiveness in SLE and could be a new target of therapeutic intervention.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25101889     DOI: 10.1126/scitranslmed.3009131

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  64 in total

1.  Foxo3 Promotes Apoptosis of B Cell Receptor-Stimulated Immature B Cells, Thus Limiting the Window for Receptor Editing.

Authors:  Kristina Ottens; Rochelle M Hinman; Evan Barrios; Brian Skaug; Laurie S Davis; Quan-Zhen Li; Diego H Castrillon; Anne B Satterthwaite
Journal:  J Immunol       Date:  2018-06-27       Impact factor: 5.422

Review 2.  MicroRNA regulation of lymphocyte tolerance and autoimmunity.

Authors:  Laura J Simpson; K Mark Ansel
Journal:  J Clin Invest       Date:  2015-06-01       Impact factor: 14.808

Review 3.  Calcium Signaling: From Normal B Cell Development to Tolerance Breakdown and Autoimmunity.

Authors:  Patrice Hemon; Yves Renaudineau; Marjolaine Debant; Nelig Le Goux; Sreya Mukherjee; Wesley Brooks; Olivier Mignen
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

4.  Developing connections amongst B lymphocytes and deregulated pathways in autoimmunity.

Authors:  Moncef Zouali; Gregory Tsay
Journal:  Mol Med       Date:  2016-10-05       Impact factor: 6.354

5.  Connective tissue diseases: A mechanism of B cell hyperactivity in SLE.

Authors:  Nicholas J Bernard
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

6.  The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.

Authors:  Lee Ann Garrett-Sinha; Alyssa Kearly; Anne B Satterthwaite
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

7.  Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity.

Authors:  Takayuki Katsuyama; Hao Li; Denis Comte; George C Tsokos; Vaishali R Moulton
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 8.  DNA methylation alterations in the pathogenesis of lupus.

Authors:  S H Chen; Q L Lv; L Hu; M J Peng; G H Wang; B Sun
Journal:  Clin Exp Immunol       Date:  2016-11-01       Impact factor: 4.330

9.  Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.

Authors:  Qingyu Zeng; Zhihan Zhou; Shanshan Qin; Yajie Yao; Jiamin Qin; Hai Zhang; Ruijie Zhang; Chong Xu; Shuangquan Zhang; Shile Huang; Long Chen
Journal:  Cell Calcium       Date:  2020-02-07       Impact factor: 6.817

10.  Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus.

Authors:  Li-Dan Zhao; Di Liang; Xiang-Ni Wu; Yang Li; Jing-Wen Niu; Chen Zhou; Li Wang; Hua Chen; Wen-Jie Zheng; Yun-Yun Fei; Fu-Lin Tang; Yong-Zhe Li; Feng-Chun Zhang; Wei He; Xue-Tao Cao; Xuan Zhang
Journal:  Cell Mol Immunol       Date:  2016-09-26       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.